Clinical trials: Metastatic Kidney Carcinoma
Advanced or Metastatic Hepatocellular Cancer, Advanced or Metastatic Ovarian Cancer
A Study With Tasquinimod Treating Patients With Hepatocellular, Ovarian, Renal Cell and Gastric Cancers
This was an exploratory proof of concept study to determine the clinical activity of tasquinimod in patients with advanced or metastatic hepatocellular carcinoma, ovarian carcinoma, renal cell carcinoma and gastric carcinoma who…
- Conditions
- Advanced or Metastatic Hepatocellular Cancer, Advanced or Metastatic Ovarian Cancer, Metastatic Renal Cell Cancer, Advanced or Metastatic Gastric Carcinoma
- Trial name
- NCT01743469
- Testing
- Tasquinimod
- Where
- 24 sites in Belgium, Canada and 3 more
- Volunteers
- 201 people
- Sponsor
- Ipsen
Breast Cancer Metastatic, Renal Cell Carcinoma (RCC)
Sapu003 in Advanced mTOR-sensitive Solid Tumors
This is a phase 1b, open-label, dose-escalation study to evaluate the safety, tolerability, pharmacokinetics of Sapu003 in combination with Exemestane in in patients with advanced mTOR-sensitive solid tumors (HR+/HER2-negative…
- Conditions
- Breast Cancer Metastatic, Renal Cell Carcinoma (RCC), Neuroendocrine Tumors, Tuberous Sclerosis Complex (TSC)
- Trial name
- NCT07369505
- Testing
- Sapu003, Exemestane 25 MG
- Where
- Australia
- Volunteers
- 27 people
- Sponsor
- SAPU NANO (US) LLC
Solid Tumor, Renal Cell Cancer Metastatic
A Study to Evaluate Safety, Efficacy, and Pharmacokinetics in Participants With Advanced Solid Tumors
Phase 1 (Dose Escalation) of this study will assess the safety, tolerability, dose-limiting toxicity (DLT), and will determine the maximum tolerated dose (MTD) and recommended Phase 2 dose (RP2D) of EU101 in participants with…
- Conditions
- Solid Tumor, Renal Cell Cancer Metastatic, Non-Small Cell Lung Cancer, Renal Cell Carcinoma
- Trial name
- NCT04903873
- Testing
- EU101
- Where
- 6 sites in United States, South Korea
- Volunteers
- 110 people
- Sponsor
- Eutilex
Renal Cancer, Metastases
68Ga-PSMA PET in the Renal Cell Carcinoma
The primary research purpose is to evaluate the diagnostic efficacy of 68Ga-PSMA PET in metastatic lesions of locally advanced and advanced renal cell carcinoma, and to compare with that of enhanced CT.
- Conditions
- Renal Cancer, Metastases, PSMA PET
- Trial name
- NCT04987086
- Testing
- PSMA PET
- Where
- 9 sites in China
- Volunteers
- 300 people
- Sponsor
- Xijing Hospital
Anaplastic Astrocytoma, Anaplastic Oligoastrocytoma
Vaccine Therapy With or Without Sirolimus in Treating Patients With NY-ESO-1 Expressing Solid Tumors
This phase I trial studies the side effects and best schedule of vaccine therapy with or without sirolimus in treating patients with cancer-testis antigen (NY-ESO-1) expressing solid tumors.
- Conditions
- Anaplastic Astrocytoma, Anaplastic Oligoastrocytoma, Anaplastic Oligodendroglioma, Estrogen Receptor Negative
- Trial name
- NCT01522820
- Testing
- DEC-205/NY-ESO-1 Fusion Protein CDX-1401, Laboratory Biomarker Analysis, Pharmacological Study
- Where
- United States
- Volunteers
- 18 people
- Sponsor
- Roswell Park Cancer Institute
Cancer
Immunotherapy in Treating Patients Who Are Undergoing Bone Marrow or Peripheral Stem Cell Transplantation
RATIONALE: White blood cells from donors who have been exposed to cytomegalovirus may be able to help prevent this infection from occurring in patients who are undergoing bone marrow or peripheral stem cell transplantation.
- Trial name
- NCT00002673
- Testing
- infection prophylaxis and management
- Where
- United States
- Volunteers
- 30 people
- Sponsor
- Fred Hutchinson Cancer Center
Cancer
High-Dose Combination Chemotherapy Plus Peripheral Stem Cell Transplantation in Treating Patients With Advanced Cancer
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Peripheral stem cell transplantation may allow the doctor to give higher doses of chemotherapy drugs and kill…
- Trial name
- NCT00002854
- Testing
- filgrastim, carboplatin, cisplatin
- Where
- United States
- Volunteers
- 33 people
- Sponsor
- City of Hope Medical Center
Bladder Cancer, Transitional Cell Cancer of the Renal Pelvis and Ureter
Gemcitabine Hydrochloride, Cisplatin, and Temsirolimus as First-Line Therapy in Treating Patients With Locally Advanced and/or Metastatic Transitional Cell Cancer of the Urothelium
RATIONALE: Drugs used in chemotherapy, such as gemcitabine hydrochloride and cisplatin, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing.
- Conditions
- Bladder Cancer, Transitional Cell Cancer of the Renal Pelvis and Ureter, Urethral Cancer
- Trial name
- NCT01090466
- Testing
- cisplatin, gemcitabine hydrochloride, temsirolimus
- Where
- United Kingdom
- Volunteers
- 15 people
- Sponsor
- Cardiff University
Metastatic Renal Cell Carcinoma
Study in Which Therapy is Either Switched to Nivolumab After 3 Months of Treatment or Therapy is Continued With a Tyrosine Kinase Inhibitor in Patients With Metastatic Renal Cell Carcinoma (RCC) and Disease Control
This study aims to assess the survival benefit from an early switch approach from sunitinib or pazopanib (10-12 weeks of 1st-line therapy) to nivolumab (anti-angiogenic to immunotherapy switch).
- Trial name
- NIVOSWITCH (NCT02959554)
- Testing
- Nivolumab, Sunitinib, Pazopanib
- Where
- 2 sites in Austria, Germany
- Volunteers
- 49 people
- Sponsor
- AIO-Studien-gGmbH
Recurrent Renal Cell Carcinoma, Stage IV Renal Cell Cancer
Cediranib Maleate in Treating Patients With Recurrent or Metastatic Kidney Cancer That Cannot Be Removed By Surgery
This phase II trial studies how well cediranib maleate works in treating patients with recurrent or metastatic kidney cancer that cannot be removed by surgery.
- Trial name
- NCT00227760
- Testing
- Cediranib Maleate, Dynamic Contrast-Enhanced Magnetic Resonance Imaging, Laboratory Biomarker Analysis
- Where
- 6 sites in Canada
- Volunteers
- 44 people
- Sponsor
- National Cancer Institute (NCI)
Clear Cell Renal Carcinoma, Urothelial Carcinoma
Safety and Efficacy of TT-00420 Tablets Combined With Toripalimab Injection in Advanced Urological Tumors
This Phase Ib/II clinical study is an open-label, multi-cohort, two-stage trial designed to assess the safety and efficacy of different doses of TT-00420 tablets in combination with Toripalimab injection for treating patients…
- Conditions
- Clear Cell Renal Carcinoma, Urothelial Carcinoma, Metastatic Castration-resistant Prostate Cancer
- Trial name
- NCT06221774
- Testing
- TT-00420 + Toripalimab
- Where
- China
- Volunteers
- 42 people
- Sponsor
- The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School
Sarcoma, Neuroblastoma
A Pilot Study of Tumor Cell Vaccine for High-risk Solid Tumor Patients Following Stem Cell Transplantation
Localized solid tumors such as, sarcoma, neuroblastoma, and Wilms' tumor, can generally be effectively treated with a combination of surgery, radiation and chemotherapy.
- Conditions
- Sarcoma, Neuroblastoma, Wilm's Tumor
- Trial name
- NCT00405327
- Testing
- Tumor lysate-pulsed dendritic cell (DC) vaccine, Hematopoietic stem cell transplantation (HSCT)
- Where
- United States
- Volunteers
- 16 people
- Sponsor
- University of Michigan Rogel Cancer Center
Metastatic Renal Cell Carcinoma
Velcade and Sorafenib in Unresected or Metastatic Renal Cell Carcinoma
This is an open label, non-randomized, single arm phase II study. The primary objective of this study is to investigate the efficacy of combination of sorafenib and VELCADE® (bortezomib).
- Trial name
- NCT01100242
- Testing
- Velcade and Sorafenib
- Where
- 3 sites in United States
- Volunteers
- 17 people
- Sponsor
- New Mexico Cancer Research Alliance
Bladder Cancer, Transitional Cell Cancer of the Renal Pelvis and Ureter
Combination Chemotherapy in Treating Patients With Advanced Bladder or Kidney Cancer
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Combining more than one drug may kill more tumor cells.
- Trial name
- NCT00003342
- Testing
- filgrastim, carboplatin, doxorubicin hydrochloride
- Where
- 2 sites in United States
- Volunteers
- 30 people
- Sponsor
- Memorial Sloan Kettering Cancer Center
Urothelial Carcinoma, Renal Cancer
Research of Double-positive Circulating Cells (Tumor Marker / CD45+) in Several Types of Metastatic Cancers
A prospective, proof-of-concept pilot study in patients with metastatic cancers (9 types of cancers are studied) treated at the IUCT-O or possibly in other institutions.
- Conditions
- Urothelial Carcinoma, Renal Cancer, Prostate Adenocarcinoma, Adenocarcinoma of Endometrium
- Trial name
- DP-PAN-CANCER (NCT06967961)
- Testing
- For each enrolled patient, the sample described below will be collected as specific intervention intended for research purposes:
- Where
- France
- Volunteers
- 450 people
- Sponsor
- Institut Claudius Regaud
Vertebral Metastasis
Conformal High Dose Intensity Modulated Radiation Therapy for Disease to Thoracic and Lumbar Spine
The purpose of this study is to determine if Conformal High Dose Intensity Modulated Radiation Therapy is an appropriate option for treating cancer that has spread to the spinal column.
- Trial name
- NCT01654068
- Testing
- Conformal High Dose Intensity Modulated Radiation Therapy
- Where
- United States
- Volunteers
- 14 people
- Sponsor
- Ronald McGarry
Metastatic Renal Cell Carcinoma ( mRCC), OligoProgressive Metastatic Disease
Radiotherapy in Combination With Checkpoint Inhibition for Patients With Metastatic Kidney Cancer
To evaluate the impact of combining innate immune system activation (with IMSA101) with antigen release (through SAbR/PULSAR) on limited progressing lesions during ongoing adaptive immune system activation (with maintenance Nivo).
- Trial name
- SPARK (NCT06601296)
- Testing
- IMSA101
- Where
- United States
- Volunteers
- 15 people
- Sponsor
- University of Texas Southwestern Medical Center
Kidney Cancer
Bevacizumab and Interleukin-2 in Treating Patients With Metastatic Kidney Cancer
RATIONALE: Monoclonal antibodies, such as bevacizumab, can block tumor growth in different ways. Some block the ability of tumor cells to grow and spread.
- Trial name
- NCT00301990
- Testing
- aldesleukin, bevacizumab
- Where
- 11 sites in United States
- Volunteers
- 65 people
- Sponsor
- Jonsson Comprehensive Cancer Center
Kidney Cancer
PS-341 in Treating Patients With Metastatic Kidney Cancer
RATIONALE: Drugs used in chemotherapy use different ways to stop cancer cells from dividing so they stop growing or die. PURPOSE: Phase II trial to study the effectiveness of PS-341 in treating patients who have metastatic kidney…
- Trial name
- NCT00017329
- Testing
- bortezomib
- Where
- United States
- Sponsor
- Memorial Sloan Kettering Cancer Center
Metastatic Cancer, Metastatic Melanoma
Modified White Blood Cells That Secrete IL-2 and Express a Protein That Targets the ESO-1tumor Protein for Metastatic Cancer
Background: A new cancer treatment involves collecting white blood cells from an individual, modifying them to secrete IL-2 and target the ESO-1 protein expressed on some cancers, and returning them to the body.
- Conditions
- Metastatic Cancer, Metastatic Melanoma, Metastatic Renal Cancer
- Trial name
- NCT01457131
- Testing
- Fludarabine, Cyclophosphamide, IL-12 & Anti-NY ESO1 TCR PBL
- Where
- United States
- Volunteers
- 2 people
- Sponsor
- National Cancer Institute (NCI)
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.